• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 20, 2018

View Archived Issues

BenevolentAI raises $115M to expand AI-based drug development

BenevolentAI Ltd., an artificial intelligence (AI)-driven drug discovery firm that sees the pharmaceutical industry as ripe for disruption, has raised $115 million to scale up its drug development activities, broaden its disease focus and hire new talent. Since 2013, it has raised more than $200 million, including the latest inflow, sourced primarily from U.S. investors. Read More

Other news to note

Capricor Therapeutics Inc., of Los Angeles, reported preclinical data for multiple treatments of its cellular therapy, CAP-1002, at the 11th Annual Neuromuscular Translational Research Conference in Cambridge, U.K. In the mdx mouse model of Duchenne muscular dystrophy, multiple administrations were possible due to the low immunogenic profile and immunomodulatory capabilities of the drug.  Read More

Appointments & advancements

TCR2 Therapeutics Inc., of Cambridge, Mass., appointed Ian Somaiya chief financial officer. Read More

Regulatory front

The U.S. Department of Health and Human Services and other federal departments are once again proposing a delay in the compliance date for the 2018 requirements for the protection of human subjects in federally supported research.  Read More

Financings

Oasmia Pharmaceutical AB, of Uppsala, Sweden, completed the private placement of a new convertible loan for SEK26 million (US$3.1 million) at an interest rate of 8 percent.  Read More

Clinical data for April 19, 2018

Read More

Study finds silver lining for meningeal damage

Researchers have found that in the case of a mild concussion, damage to the lining of the brain was quickly repaired by the peripheral immune system, and once repaired, was no worse for wear in the face of a second injury. Read More

Multimorbidity on the rise, says report; strategy needed for treatment, clinical trials

LONDON – A rapid rise in the incidence of multimorbidity is calling into question treatment guidelines and the applicability of the evidence on which many drugs are prescribed, according to a panel of 17 international health experts in a new report. Read More

Timing hurts Surface, shares encounter rough SURF on Nasdaq

Surface Oncology Inc. picked a day when the U.S. financial markets were flowing solid red to price its upsized IPO of 7.2 million common shares at $15 apiece – the high end of its proposed range – and raise $108 million. The Cambridge, Mass.-based company added $11.5 million in a concurrent private placement of 766,666 additional shares to Novartis Institutes for Biomedical Research Inc. at the IPO price. A 30-day option to underwriters to purchase up to 1.08 million additional common shares could add $16.2 million to Surface's haul. Read More

Morphosys grosses $208M in Nasdaq listing, exceeding initial target; Mereo on deck

DUBLIN – Veteran German antibody developer Morphosys AG swelled the ranks of European biotech firms on Nasdaq by grossing $207.8 million from an offering of 8.3 million American depositary shares, which it priced at $25.04 per share. If exercised, an overallotment option comprising 1.245 million shares would add another $37.35 million to the proceeds. Shares in the Martinsried-based firm began trading today under the ticker symbol MOR, and quickly went into positive territory, reaching $26.47 at one point and ending the day at $26.31. Read More

Argos won't ADAPT, bows to futility on roca-T phase III and weighs M&A prospects

More than a year after an independent data monitoring committee (IDMC) suggested that Argos Therapeutics Inc. halt the pivotal phase III ADAPT trial of lead candidate rocapuldencel-T (roca-T, formerly AGS-003) for futility, the Durham, N.C.-based company threw in the towel and said it was exploring a range of strategic alternatives, including a potential merger or sale of the company. Read More

No walk in the park for Lilly RA drug as it heads to FDA adcom

A year after receiving a complete response letter (CRL), Eli Lilly and Co. is heading to the FDA Arthritis Advisory Committee Monday to make its case for baricitinib. But as one analyst indicated, it won't be a walk in the park. Read More

GW wins panel nod; 'floodgates to open' via cannabis progress

Advances made during the last five to seven years in cannabis-based therapies equal about 50 years' worth of the same in the pharmaceutical industry overall, George Scorsis, CEO of Liberty Health Sciences Inc., told BioWorld. Federal legislation to enable more experiments with marijuana will keep the pace brisk, along with work by the likes of GW Pharmaceuticals plc. Read More

Shire rejects Takeda's $62B cash, shares offer while Allergan steps in and out

DUBLIN – Allergan plc threatened to disrupt Takeda Pharmaceutical Co. Ltd.'s ongoing wooing of Shire plc by confirming Thursday in response to press speculation that it was "in the early stages of considering a possible offer for Shire." The news drove Shire's stock about 6 percent higher as investors positioned themselves as beneficiaries in a possible bidding war. Three hours later, Dublin-based Allergan issued a terse follow-up statement: "In order to comply with the requirements of the U.K. takeover code, Allergan announced that it does not intend to make an offer for Shire." Read More

Regulatory actions for April 19, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe